CD8A and melanoma: To test this hypothesis in melanoma, mice carrying BP tumors and treated with LTX-315 received anti-CD8 depleting antibodies to reduce the number of CD8+ T cells during the 15 days following LTX-315 treatment (Fig. 3G).